Amplia Therapeutics Limited, is pleased to announce that the US FDA have cleared Amplia’s IND application for a trial of Amplia’s best-in-class focal adhesion kinase inhibitor narmafotinib in pancreatic cancer.
Amplia Therapeutics Limited, is pleased to announce that the US FDA have cleared Amplia’s IND application for a trial of Amplia’s best-in-class focal adhesion kinase inhibitor narmafotinib in pancreatic cancer.